Notably, reductions in NfL levels have been associated with slowed disease progression in ALS patients receiving the antisense oligonucleotide therapy Tofersen for SOD1-driven ALS [47, 48], making our findings particularly relevant in the context of senolytic treatment. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.